DOCSLIB.ORG

IFCC-Worldlab BERLIN 2011

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
IFCC-Worldlab BERLIN 2011 UnderUnder thethe AuspicesAuspices of:of: FIT FOR FUTURE - HELP HEALING THE WORLD Asian and Pacific Federation of Clinical Biochemistry 21st International Congress of Clinical Chemistry and Laboratory Medicine 19th IFCC-EFCC European Congress of Clinical Chemistry and Laboratory Medicine Clinical and Laboratory Standards Institute 8th Annual Meeting of the German Society of Clinical Chemistry and Laboratory Medicine Berlin, Germany World Association of Societies of Pathology and Laboratory Medicine ICC Berlin - Internationales Congress Centrum 15 - 19 May 2011 FINALFINAL PROGRAMPROGRAM Bundesministerium für Bildung und Forschung SUNDAY 15 MAY 16:45-17:45 Workshop ABBOTT HALL 7 15:30-16:30 Workshop IRIS HALL 4/5 14:30-16:30 DGKL 6 HALL 9 SUNDAY 15 MAY OVARIAN CANCER BIOMARKERS IN THE CLINICAL CONTEXT - STRATIFICATION AND THE CLINICAL UTILITY OF REFLEX URINE CULTURES BASED ON URINALYSIS AND RESEARCH FUNDING BY THE FOUNDATION OF PATHOBIOCHEMISTRY AND MOLECU- 17.30 - 19.30 HALL 1 MONITORING AUTOMATED URINE MICROSCOPY USING THE IQ200 WORKSTATION LAR DIAGNOSTICS OF THE DGKL OPENING CEREMONY 16:45-17:45 Workshop SEBIA HALL 4/5 16:45-17:45 Workshop HORIBA HALL 8 14:30-16:00 INTERACTIVE 1 HALL 10 HBA1C: EW BREAKTHROUGH TECHNOLOGY FOR LABORATORIES FACING A THE “LEAN” ALTERNATIVE CHALLENGES AT THE CLINICAL INTERFACE MONDAY 16 MAY CHANGE OF PARADIGM 16:45-17:45 Workshop ROCHE HALL 14.2 15:30-16:30 Workshop RANDOX HALL 14.2 9:00-11:00 SYMPOSIUM 1 HALL 1 16:45-17:45 Workshop OSM HALL 9 EFFICIENT LAB ORGANIZATION FROM PRE-TO POST ANALYTIC CURRENT AND FUTURE PERSPECTIVES IN DRUGS OF ABUSE SCREENING; THE MUL- BIOMARKERS FOR THE DIAGNOSIS OF CARDIOVASCULAR DISEASES ZENTRALLABOR VS. VERBUNDLABOR TIPLEX APPROACH 16:45-17:45 Workshop ABBOTT HALL 7 9:00-11:00 SYMPOSIUM 2 HALL 3 16:45-17:45 Workshop AXIS SHIELD HALL 10 AUTOMATION TO ENSURE YOUR LAB’S EFFICIENCY 15:30-16:30 Workshop BIOSYSTEMS HALL 4/5 DIAGNOSTIC CHALLENGES IN LIVER DISEASE USING ACTIVE B12 TO DIAGNOSE VITAMIN B12 DEFICIENCY TRACEABILITY AND UNCERTAINTY OF CATALYTIC ACTIVITY MEASUREMENTS 16:45-17:45 Workshop BECTON HALL 4/5 9:00-11:00 YEAR IN REVIEW 1 HALL DICKINSON CLINICAL CHEMISTRY 2010 AND BEYOND: OPPORTUNITIES AND CHALLENGES FOR COUNTING THE COST OF THE PREANALYTICAL PHASE THE NEXT DECADE TUESDAY 17 MAY THURSDAY 19 MAY 9:00-11:00 SYMPOSIUM 7 HALL 1 9:00-11:00 SYMPOSIUM 17 HALL 1 16:45-17:45 Workshop SIEMENS HALL 9 9:00-11:00 SYMPOSIUM 3 HALL 14.2 PHARMACOGENETIC AND PHARMACOGENOMIC NEW HIGH-PERFORMANCE ASSAYS FOR THE DETERMINATION OF FREE LIGHT NEW STRATEGIES IN MOLECULAR DIAGNOSTIC TUMOR MARKERS IN CANCER CHAIN KAPPA AND LAMBDA - ADDING CONSISTENCY TO MONITORING AND 9:00-11:00 YEAR IN REVIEW 2 HALL 3 9:00-11:00 SYMPOSIUM 18 HALL 3 SCREENEING OF MULTIPLE MYELOMA 9:00-11:00 IFCC 1 HALL 7 ADVANCES IN CLINICAL CHEMISTRY IN THE FIELD OF NEPHROLOGY AND STANDARDIZATION AND QUALITY CONTROL ISSUES IN EMERGING AND e-LEARNING AND DISTANCE EDUCATION IN CLINICAL CHEMISTRY AND LABORA- ENDOCRINOLOGY 16:45-17:45 Workshop PERKINELMER HALL 10 DEVELOVING COUNTRIES TORY MEDICINE CLINICAL MSMS - NEW DEVELOPMENTS IN TODAY’S LABORATORY 9:00-10:30 WORKSHOP 3 HALL 8 9:00-10:30 WORKSHOP 10 HALL 8 9:00-11:00 SYMPOSIUM 4 HALL 4/5 OXIDATIVE STRESS IN DIABETES MELLITUS STANDARDIZATION OF COMPLEX ANALYTE MEASUREMENT: THE CLINBIOTRACE ACUTE AND CHRONIC KIDNEY DISEASES. AN UPDATE PROJECT 9:00-11:00 SYMPOSIUM 8 HALL 14.2 WEDNESDAY 18 MAY 9:00-11:00 DGKL 1 HALL 9 INFECTIOUS DISEASES 9:00-11:00 SYMPOSIUM 12 HALL 1 9:00-11:00 SYMPOSIUM 19 HALL 14.2 ROLE OF NON-MEDICAL SCIENTISTS BIOMARKERS IN ACUTE AND CHRONIC BRAIN DISEASES CURRENT CHALLANGES IN THE PEDIATRIC LABORATORY 9:00-11:00 DGKL 3 HALL 7 9:00-10:30 WORKSHOP 1 HALL 10 BIOCHEMICAL ANALYSIS PRIZE - AWARD CEREMONY 9:00-11:00 YEAR IN REVIEW 3 HALL 3 9:00-11:00 EFCC 4 HALL 7 REPORTING HbA1c FOR MONITORING AND DIAGNOSIS: THE DEVIL’S IN THE DETAIL DEVELOPMENTS IN CLINICAL LABORATORY PRACTICE STANDARDIZATION OF THE PRE-ANALYTICAL PHASE FOR BIOMARKERS 9:00-11:00 SYMPOSIUM 9 HALL 4/5 11:30-12:45 PLENARY SESSIONS HALL 1 HAEMATOLOGY AND ANEMIA 9:00-10:30 WORKSHOP 7 HALL 8 9:00-11:00 SYMPOSIUM 20 HALL 4/5 MOLECULAR TUMOR DIAGNOSTICS CLINICAL PHARMACOGENETIC VITAMIN D: MYTH OR MAGIC 9:00-11:00 IFCC 2 HALL 9 13:00 - 14:00 Workshop ORTHO HALL 8 BIOBANKING AND LABORATORY MEDICINE: TWO RESOURCES FOR MODERN 9:00-11:00 SYMPOSIUM 13 HALL 14.2 9:00-10:30 WASPaLM WS HALL 9 CLINICAL DIAGNOSTICS HEALTH CARE PRENATAL AND NEONATAL SCREENING CHRONIC KIDNEY DISEASE - DEVELOPING A NATIONAL TESTING PROGRAM TESTING FOR VITAMIN D DEFICIENCY: DEFINING AT-RISK POPULATIONS 9:00-10:30 WORKSHOP 4 HALL 10 9:00-11:00 IFCC 3 HALL 7 9:00-10:30 WORKSHOP 11 HALL 10 13:00 - 14:00 Workshop BECKMAN HALL 14.2 UPDATE ON CARDIAC TROPONIN - CLINICAL AND LABORATORY ISSUES STANDARDIZATION IN MOLECULAR DIAGNOSTICS BIOMARKERS OF ACUTE AND NEURODEGENERATIVE BRAIN DAMAGES COULTER CLINICAL AND ECONOMIC ADVANCES IN PROSTATE CANCER DIAGNOSIS 11:30-12:45 PLENARY SESSIONS HALL 1 9:00-11:00 SYMPOSIUM 14 HALL 4/5 11:30-12:45 PLENARY SESSIONS HALL 1 ADVANCES IN CLINICAL AND DIAGNOSTIC IMMUNOLOGY ALLERGY DIAGNOSTICS NEW AVENUES IN LABORATORY DIAGNOSTICS 13:00 - 14:00 Workshop ABBOTT HALL 7 IMPORTANCE OF BIOMARKERS IN OPTIMISING THE TREATMENT OF PATIENTS WITH 13:00 - 14:00 Workshop RANDOX HALL 8 9:00-11:00 DGKL 5 HALL 9 13:00 - 14:00 Workshop LABS ARE HALL 8 HEART AND KIDNEY DISEASE INCREMENTAL VALUE OF H-FABP IN AN AREA OF HIGHLY SENSITIVE TROPONINS DEVELOPMENT OF A TRANSCRIPTOMIC, PROTEOMIC AND METABOLOMIC VITAL DATABASE FOR HUMAN BLOOD CELLS ADDING VALUE TO LABORATORY MEDICINE 13:00 - 14:00 Workshop SYSMEX HALL 4/5 13:00 - 14:00 Workshop BECKMAN HALL 14.2 TRUST BY VERIFY: HOW TO EVALUATE HAEMATOLOGY SYSTEMS COULTER 9:00-10:30 WORKSHOP 8 HALL 10 13:00 - 14:00 Workshop WATERS HALL 9 FROM CLINICAL CHEMISTRY TO MOLECULAR DIAGNOSTICS: INNOVATIVE MOLECULAR DIAGNOSIS OF INFECTION LC/MS IN THE CLINICAL LABORATORY - 13:00 - 14:00 Workshop SIEMENS HALL 9 SOLUTIONS FOR LABORATORY AUTOMATION AND ORGANISATION TRANSITION FROM A RESEARCH TOOL TO ROUTINE CLINICAL LABORATORY USE THE VALUE OF IMPROVED WORKFLOW SOLUTIONS 11:30-12:45 PLENARY SESSIONS HALL 1 13:00 - 14:00 Workshop ABBOTT HALL 7 THE BRAIN: BIOLOGICAL AND CEREBRAL DISEASES 14:30-16:30 SYMPOSIUM 21 HALL 1 13:00 - 14:00 Workshop ZMBD HALL 10 LABORATORY DIAGNOSIS OF HEPATITIS C - WHAT ARE LOOKING FOR? NEW TECHNOLOGIES IN CLINICAL APPLICATION IMPACT OF NEW OMICS-PLATFORMS ON BIOMARKERS DISCOVERY AND 13:00 - 14:00 Workshop RANDOX HALL 8 APPLICATIONS 13:00 - 14:00 Workshop SYSMEX HALL 4/5 THE USE OF MULTIPLEX ASSAYS FOR DETERMINING PREDISPOSITION TO 14:30-16:30 SYMPOSIUM 22 HALL 3 TRUST BY VERIFY: HOW TO EVALUATE HAEMATOLOGY SYSTEMS HYPERTENSION INTERWINING EMERGENCY MEDICINE AND LABORATORY MEDICINE 13:30 - 14:30 POSTER AREA POSTER WALKS 13:00 - 14:00 Workshop A.MENARINI HALL 9 13:00 - 14:00 Workshop BECKMAN HALL 14.2 14:30-16:00 WORKSHOP 12 HALL 8 FOCUS ON NEW DIAGNOSTIC STRATEGIES IN AUTOIMMUNITY COULTER TRENDS IN THERAPEUTIC DRUG MONITORING: PERSONALIZED 14:15-15:15 Workshop RANDOX HALL 14.2 NOVEL MARKERS IN REPRODUCTIVE ENDOCRINOLOGY IMMUNOSUPPRESSION THE CLINICAL UTILITY OF MULTIPLEX BIOCHIPS FOR THE DETECTION OF MULTIPLE 13:00 - 14:00 Workshop ORTHO HALL 10 STI’S AND RESPIRATORY PATHOGENS CLINICAL DIAGNOSTIC 13:00 - 14:00 Workshop ABBOTT HALL 7 14:30-16:30 IFCC 4 HALL 7 ENHANCING PATIENT CARE IN THE CHALLENGING DIAGNOSTICS ARENA IN EUROPE VITAMIN D AND B12 - IMMUNOASSAYS IN PREVENTIVE MEDICINE TRACEABILITY, STANDARDIZATION, HARMONISATION: CONCEPTS AND 14:15-15:15 Workshop A.MENARINI HALL 4/5 IMPLEMENTATION SEDIMAX: RECENT AND SIGNIFICANT ADVANCES IN AUTOMATED URINE SEDIMENT 13:30 - 14:30 POSTER AREA 13:00 - 14:00 Workshop SYSMEX HALL 4/5 EXAMINATION POSTER WALKS WORK AREA MANAGEMENT: THE ULTIMATE PRODUCTIVITY TOOL 14:30-16:00 WORKSHOP 13 HALL 9 VITAMIN DEFICIENCY IN ELDERLY PEOPLE: DIAGNOSIS, PREVENTION AND EFFECT 14:30-16:30 SYMPOSIUM 5 HALL 1 14:15-15:15 Workshop BECKMAN HALL 14.2 13:00 - 14:00 Workshop THE HALL 9 ON AGE-RELATED DISEASES FROM BENCH TO BEDSIDE IN AUTOIMMUNITY COULTER BINDING SITE NEW HORIZONS IN CELLULAR ANALYSIS FreeliteTM AND HevyliteTM IN MONOCLONAL GAMMAPATHIES: IMPROVING DIAGNOSIS, 14:30-16:00 WORKSHOP 14 HALL 10 14:30-16:30 SYMPOSIUM 6 HALL 3 MONITORING AND PROGNOSIS ASSESSMENT NOVEL INSIGHTS IN IRON METABOLISM: IMPLICATIONS FOR DIAGNOSTIC MEDICINE DIABETES MELLITUS 14:15-15:15 Workshop SIEMENS HALL 4/5 DIAGNOSTIC AND CLINICAL IMPORTANCE OF MEASURING VITAMIN D TOTAL 13:00 - 14:00 Workshop DIASORIN HALL 10 16:30-17:30 HALL 1 14:30-16:00 WORKSHOP 2 HALL 8 VITAMIN D DIETARY REFERENCE INTAKES: IMPLICATIONS AND SIGNIFICANCE IN CLOSING CEREMONY EMERGING INFECTIONS AT AFCB COUNTRIES 14:30-16:30 SYMPOSIUM 10 HALL 1 CLINICAL PRACTICE DIAGNOSTIC USE AND VALUE OF FUCTION TEST IN ENDOCRINOLGY 14:30-16:30 EFCC 1 HALL 7 13:30 - 14:30 POSTER AREA HOW TO ASSESS THE CLINICAL EFFECTIVENESS OF LABORATORY TESTS? 14:30-16:30 SYMPOSIUM 11 HALL 3 POSTER WALKS POINT OF CARE TESTING - PRACTICAL ASPECTS 14:30-16:30 DGKL 2 HALL 9 14:15-15:15 Workshop ROCHE HALL 14.2 LABORATORY MEDICINE - QUO VADIS? 14:30-16:00 WORKSHOP 5 HALL 8 PERSONALISED HEALTHCARE AS A KEY DRIVER FOR PRESENT AND FUTURE SOCIAL EVENTS CONDITIONS, STRUCTURES AND DEVELOPMENTAL TRENDS IN EUROPE LESSONS FROM ASIAN-PACIFIC MULTICENTER REFERENCE INTERVAL STUDY DIAGNOSTIC/THERAPEUTIC STRATEGIES Sunday 15 May 14:30-16:00 INTERACTIVE 2 HALL 10 14:30-16:30 DGKL 4 HALL 7 14:15-15:15 Workshop DIASYS HALL 4/5 19:30 Welcome Party PITFALLS IN THE HEMOSTASIOLOGIC DIAGNOSTICS: CLINICAL CASES QUALITY MANAGEMENT ACCORDING
Load more

Recommended publications
  • October 24–26, 2021 2
    SCIENCE · INNOVATION · POLICIES WORLD HEALTH SUMMIT BERLIN, GERMANY & DIGITAL OCTOBER 24–26, 2021 2 “No-one is safe from COVID-19; “All countries have signed up to Universal no-one is safe until we are all Health Coverage by 2030. But we cannot safe from it. Even those who wait ten years. We need health systems conquer the virus within their that work, before we face an outbreak own borders remain prisoners of something more contagious than within these borders until it is COVID-19; more deadly; or both.” conquered everywhere.” ANTÓNIO GUTERRES Secretary-General, United Nations FRANK-WALTER STEINMEIER Federal President, Germany “We firmly believe that the “All pulling together—this must rights of women and girls be the hallmark of the European are not negotiable.” Health Union. I believe this can NATALIA KANEM be a test case for true global Executive Director, United Nations Population Fund (UNFPA) health compact. The need for leadership is clear and I believe the European Union must as- sume this responsibility.” “The lesson is clear: a strong health URSULA VON DER LEYEN system is a resilient health system. Health President, European Commission systems and preparedness are not only “Governments of countries an investment in the future, they are the that are doing well during foundation of our response today.” the pandemic have not TEDROS ADHANOM GHEBREYESUS Director-General, World Health Organization (WHO) only shown political leader- ship, but also have listened “If we don’t address the concerns and to scientists and followed fears we will not do ourselves a favor. their recommendations.” In the end, it is about how technology SOUMYA SWAMINATHAN Chief Scientist, World Health can be advanced as well as how Organization (WHO) we can make healthcare more human.” BERND MONTAG President and CEO, Siemens Healthineers AG, Germany “The pandemic has brought to light the “Academic collabo ration is importance of digital technologies and in place and is really a how it can radically bridging partnership.
    [Show full text]
  • Research Uses of Peptides from the Manning Lab 1980 – 2019
    Research Uses of Peptides from the Manning Lab 1980 – 2019 Over 3,000 samples have been donated to over 820 investigators (some multiple times) in the U.S. and worldwide for their own independent studies. See listings below. These studies have resulted in over 2,000 publications by these investigators. 1. Professor Roger Acher Laboratoire De Chimie Biologique Faculté des Sciences de l’Université de Paris 96, Boulevard Raspail-Paris V1 FRANCE 2. Eli Y. Adashi, M.D. Obstetrics & Gynecology University of Maryland School of Medicine & Hospital 22 South Greene Street Balitmore, MD 21201 3. Greti Aguilera, M.D. Chief Section on Endocrine Physiology DEB, NICHD, NIH Building 10, Room 10N262 10 Center Drive, MSC 1862 Bethesda, MD 20892-1862 4. Dr. K. Al Barazanji Mechanistic Pharmacology Dept. Vascular Biology SmithKline Beecham Pharmaceuticals The Frythe Welwyn, Hertfordshire, AL6 9AR UNITED KINGDOM 5. H. Elliott Albers, Ph.D. Professor of Biology and Psychology Georgia State University Department of Biology College of Arts and Sciences P.O. Box 4010 Atlanta, GA 30302-4010 6. Saad Al-Damluji, B.Sc., MRCP Lecturer in Endocrinology The Medical College of St. Bartholomew’s Hospital West Smithfield, LONDON, EC1A 7BE ENGLAND 7. Natalie Alexander, Ph.D. Department of Medicine University of Southern California School of Medicine 2025 Zonal Avenue Los Angeles, CA 90033 8. O.F.X. Almeida, Ph.D. Max-Planck-Institut Für Psychiatrie Deutsche Forschungsanstalt Für Psychiatrie Abteilung Neuropharmakologie AM Klopferspitz 18A 8033 Planegg-Martinsried WEST GERMANY 9. Dr. Meenakshi Alreja Associate Professor of Psychiatry and Neurobiology Yale University School of Medicine CMHC 335A, 34 Park Street New Haven, CT 06508 10.
    [Show full text]
  • World Health Summit Berlin, Germany October 09–11, 2016
    SCIENCE · INNOVATION · POLICIES WORLD HEALTH SUMMIT BERLIN, GERMANY OC TOBER 09–11, 2016 FEDERAL FOREIGN OFFICE | BERLIN I am convinced the “ World Health Summit will add valuable The World Health Summit impetus and wish all “ is an excellent venue for participants interesting expert discussion on the and enlightening days. health topics that move us Hermann Gröhe Federal Minister of Health, Germany” worldwide. We can expect it to deliver valuable input. Angela Merkel Chancellor of the ” Your involvement and Federal Republic of Germany “ your declarations at this World Health Summit will play an important role in informing the international community. François Hollande President of the French Republic ” FACTS WORLD HEALTH SUMMIT 2016 | 3 3 DAYS · 40 SESSIONS · 250 SPEAKERS From October 9–11, the 8th World Health Summit will once Patronage again draw international experts from academia, politics, Angela Merkel Federal Chancellor of Germany the private sector, and civil society to the German Federal François Hollande Foreign Oce in Berlin. President of France Jean-Claude Juncker At the World Health Summit (WHS), more than 1,500 stakeholders and President of the decision-makers from every field in the healthcare spectrum will work European Commission together to find solutions to global health challenges. Presidents 2016 The world’s foremost strategic forum for global health, it promotes thought Antoine Flahault leadership in science and global health agendas. The World Health Summit University of Geneva was founded in 2009 on the occasion
    [Show full text]
  • Global Health – Do Think Tanks Matter?
    Global Health – Do Think Tanks Matter? Organised by the Global Health Programme at the Graduate Institute Biographies of Speakers 13 November 2015 Maison de la paix The Graduate Institute, Geneva WELCOME AND INTRODUCTORY REMARKS BY THE MODERATOR OF THE SESSION ILONA KICKBUSCH Director, Global Health Programme, the Graduate Institute Ilona Kickbusch is the Director of the Global Health Programme at the Graduate Institute of International and Development Studies, Geneva. She is senior advisor to the Regional Directors of the WHO Regional Offices for Europe and the Eastern Mediterranean. She has been deeply involved in the development of the Health 2020 European health policy framework. She is a member of the independent Ebola interim assessment panel of the WHO. In Switzerland, she serves on the executive board of the Careum Foundation and on the expert panel to the Federal Councillor to advise on the implementation of the Swiss Health Strategy 2020. She has contributed to innovation in health in many ways throughout her career and now advises organisations, government agencies and the private sector on policies and strategies to promote health at the national, European and international level. She has worked with the WHO at various levels and in academia as professor at Yale University. She has received honorary doctorates from the Nordic School of Public Health and the University of Girona. She has published widely and is a member of a number of advisory boards in both the academic and health policy arenas. She has received many awards. Her key areas of work relate to Global Health Governance, Health Security, Public Health, Health Promotion, Health Literacy, and Health in All Policies.
    [Show full text]
  • Detlev Ganten
    Detlev Ganten * 28. 3. 1941 Lüneburg Der Mediziner Detlev Ganten arbeitet in der Bluthochdruckforschung und über die molekulare Genetik von Herz-Kreislauf-Erkrankungen. 1997/98 war Ganten Präsident der GDNÄ und referierte z. B. 1994 in Hamburg über Die Genetik des Bluthochdrucks: Molekulare Analyse einer Volkskrankheit. Detlev Ganten studierte ab 1962 Medizin in Würzburg, Montpellier (Frankreich) und Tübingen und war an der chirurgischen Abteilung des französischen Krankenhauses in Marrakesch tätig. Das Studium schloss er 1968 mit der Promotion ab. Zwischen 1969 und 1973 hielt er sich für For- schungszwecke am Clinical Research Institute in Montreal auf und erwarb den Doctor of Philosophy (PhD) von der McGill University. 1975 erhielt Ganten einen Ruf an das Pharmakologische Institut der Universität Heidel- berg und war anschließend ab 1992 Gründungsdirektor des Max-Delbrück- Centrums für Molekulare Medizin in Berlin-Buch. Parallel dazu war Ganten bis 2004 Professor für Klinische Pharmakologie am Universitätsklinikum der FU Berlin. In seiner wissenschaftlichen Arbeit beschäftigt sich Ganten insbesondere mit dem hormonalen Renin-Angiotensin-System, das u.a. für die Erhöhung des Blutdrucks verantwortlich ist. Daneben forscht er zur An- wendung transgener Techniken im Bereich der Herz-Kreislauf-Regulation und zu den genetischen Ursachen von Bluthochdruck. Ganten ist Heraus- geber des Journal of Molecular Medicine und des Handbook of Experimental Phar- macology. Außerhalb der wissenschaftlichen und medizinischen Arbeit war Gan- ten von 1993 bis 1998 Mitglied im Wissenschaftsrat der Bundesrepublik Deutschland, saß von 2002 bis 2007 im Nationalen Ethikrat und war von 2004 bis 2008 Vorstandsvorsitzender der Charité. Zwischen 1997 und 2001 war er Präsident der Helmholtz-Gemeinschaft Deutscher Forschungszent- ren.
    [Show full text]
  • M8 Alliance Expert Meeting on Migrants' and Refugees' Health 23
    M8 Alliance Expert Meeting on Migrants’ and Refugees’ Health 23-24 June 2017 Venue: Rectorate Building, Sapienza University of Rome, P.le Aldo Moro 5, Rome Hosted by Sapienza University of Rome in cooperation with Charité – Universitätsmedizin Berlin, the University of Geneva, the University of Montreal, the Université Sorbonne Paris Cité, the Centre Virchow-Villermé for Public Health Paris-Berlin, Tehran University of Medical Sciences and the Italian Society of Migration Medicine Overall Chair: Luciano Saso, Faculty of Pharmacy and Medicine, Vice-Rector for European University Networks Sapienza University, Sapienza's Representative in the M8 Alliance 23 June, 2017 11.00 Conferral of Honorary Doctorate on Prof. Detlev Ganten (Senate Hall, Rectorate Building, 1st floor) 13:00-14:00 Registration and light lunch (Room “Organi Collegiali”, Rectorate Building, ground floor) 14:00 -14:25 Welcome Addresses Eugenio Gaudio, Rector of Sapienza University of Rome Detlev Ganten, President of the World Health Summit, Berlin Delegate of Beatrice Lorenzin, Minister of Health, Italy Susanne Wasum-Rainer, Ambassador, Embassy of the Federal Republic of Germany in Italy Hinrich Thölken, Ambassador, Permanent Representation of the Federal Republic of Germany to the International Organizations in Italy 14:25 -14:45 Introduction Paolo Villari, Director of the Department of Public Health and Infectious Diseases, Sapienza University of Rome Axel Pries, Dean, Charité, Universitätsmedizin Berlin Vincenzo Vullo, Dean of the Faculty of Pharmacy and Medicine, Sapienza University of Rome Sebastiano Filetti, Dean of the Faculty of and Medicine and Dentistry, Sapienza University of Rome Massimo Volpe, Dean of the Faculty of and Medicine and Psychology, Sapienza University of Rome 14:45-17:00 Session 1A.
    [Show full text]
  • 2 of the Collège De France
    The Letter 2 of the Collège de France N°2 Academic year 2006-2007 Editorial The Collège de France’s new Scientific and Strategic Orientation Committee (COSS) by Pierre Corvol Administrator ‘Today’s world is seeking references, reasons to marvel, of the Collège de France ambitious motivating projects. With the sole objective of Professor, furthering knowledge, basic research – that essentially holder of the Chair of Experimental Medicine disinterested research which demands real collaboration at international level – is one of the paths on that quest. Science is and will always remain a factor of emancipation for humans the university world through the PhD schools, increasing and it is important today to emphasize that obvious fact. In this relations with foreign universities, and developing research at the context, the Collège de France has a unique position in France Collège itself. Today a progress report is indispensable. The and in Europe but also in the world.’ These are the introductory Collège will be attentive to the COSS’s opinions on these points, lines of the Annual Report of the International Scientific and as these will enable it to focus its strategy on the objectives that Strategic Orientation Committee (COSS) submitted to the the Committee has reviewed and revised. President of the Republic, the Prime Minister and the Collège de France’s supervisory ministries in May 2004. The COSS meeting in March 2007 enabled it to make contact with the members of the extended executive of the The creation of the COSS in 2003, on the Collège’s Collège and certain professors at the Cardinal Lemoine and initiative, stemmed from the wish to benefit from eminent Ulm sites.
    [Show full text]
  • World Health Summit Berlin, Germany October 15–17, 2017
    S ECCI N E · InnOVATION · POLICIES WORLD HEALTH SUMMIT B ERLIN, GERMANY O CTOBER 15–17, 2017 FACTS WORLD HEALTH SUMMIT 2017 | 3 3 DAYS · 40 SESSIONS · 250 SPEAKERS From October 15–17, the 9th World Health Summit will draw Patronage inter national experts from academia, politics, the private sector, Angela Merkel and civil society to Berlin. Chancellor of the Federal Republic of Germany At the World Health Summit (WHS), more than 1,600 stakeholders François Hollande * and decision-makers from over 80 countries and every field in the President of France healthcare spectrum will work together to find solutions to global Jean-Claude Juncker * health challenges. President of the European Commission The world’s foremost strategic forum for global health, it promotes thought leadership in science and advances global health agendas. Presidents 2017 The World Health Summit was founded in 2009 on the occasion of Hélène Boisjoly the 300th anniversary of Berlin’s Charité Hospital. Université de Montréal Detlev Ganten Charité – Universitätsmedizin Berlin PROGRAM STRUCTURE Participants SUNDAY, OCT 15, 2017 • More than 1,600 decision makers 10:30 from over 80 countries on site 13:00 • More than 3,000 people 15:00 worldwide via online live-stream 17:00 WHS OPENING CEREMONY Results • The M8 Alliance Declaration MONDAY, OCT 16, 2017 • Session Reports 9:00 • Statements and recommendations 11:00 made at the WHS are passed on to 13:00 WHS Startup Track National Academies, Governments, 14:00 and International Organizations 16:00 19:00 WHS Night Regional Meetings
    [Show full text]
  • Curriculum Vitae Professor Dr. Detlev Ganten
    Curriculum Vitae Professor Dr. Detlev Ganten Name: Detlev Ganten Born: 28 March 1941 Major scientific interests: Pathophysiology and molecular biology of high blood pressure, Public Health, Bioethics Academic and Professional Career 2010 Guest Professorship, Collège de France, Paris, France since 2009 President World Health Summit; Chairman of Board of Trustees of the Max Planck Institute of Colloids and Interfaces and Max Planck Institute of Molecular Plant Physiology, Germany since 2005 Chairman of the Board, Charité Foundation, Germany 2004 ‐ 2008 Chief Executive Officer, Charité Berlin, Germany 1991 ‐ 2004 Founding Director, Max Delbrück Center for Molecular Medicine (MDC) Berlin‐ Buch, Germany 1975 Professor of Pharmacology, University of Heidelberg, Germany 1973 Ph.D., McGill University, Montreal, Canada 1969 ‐ 1973 Research Fellow, Clinical Research Institute, Université de Montreal, Canada 1968 M.D. degree, University of Tübingen, Germany Project coordination, Membership in collaborative research projects (Selection) since 2011 Board of Trustees, University Paris Sciences Lettres PSL since 2011 Scientific Advisory Board, University Sorbonne Paris Cité since 2009 President of the World Health Summit Nationale Akademie der Wissenschaften Leopoldina www.leopoldina.org 1 since 2009 Chairman of Board of Trustees of the Max Planck Institute of Colloids and Interfaces and Max Planck Institute of Molecular Plant Physiology, Potsdam, Germany since 2009 Scientific Advisory Board, Agence Nationale der Recherche (ANR), Paris, France since
    [Show full text]
  • Value-Based Health Care in the Digital Era
    VALUE-BASED HEALTH CARE IN THE DIGITAL ERA December 18, 2018 Imagine Institute 24, Boulevard de Montparnasse 75015 Paris Sous le haut patronage de Madame Agnès Buzyn, ministre des Solidarités et de la Santé 2ND EDITION - INTERNATIONAL CONFERENCE MEMBERS OF THE SCIENTIFIC COMMITTEE CHAIRMAN OF THE SCIENTIFIC COMMITTEE We stand at an inflection point. Health systems and stakeholders are increasingly being Ran Balicer (ISR) David Bates (USA) Adam Donglei Feng (CHN) held accountable for the value their actions and products provide to patients and society at Founder and Director Professor of Health Professor, Wan Da Fullway large. Healthcare ought to be driven by a relentless focus on delivering outcomes that truly Clalit Research Policy & Management, Healthcare, General Manager & Institute Harvard T.H . Chan Co- founder Shanghai SimMed matter to patients. However, the emergence of value-based health care is hindered by a lack School of Public Health Technology Co of transparent and standardized outcome data. Digital solutions can play an instrumental role in transforming health systems in an unprecedented way. But how do we get there? We invite you to join leaders & pioneers from around the world to share experience on pilots & initiatives around the implementation of value-based health care, the adoption of digital standards, to expectations in payment reforms and access to quality healthcare. Detlev Ganten (GER) Véronique L. Roger (FRA) Lise Rochaix (FRA) Gregory Katz President & Founder Founding Director Center for Chaired Professor of Chaired Professor of Innovation Management & Value in Health University World Health Summit the Science of Health Care Health Economics, Chair Paris-Descartes Medical School, Director of Research, Elsan, Chairman of the Delivery, Mayo Clinic Hospinomics, Sorbonne University & Paris School Think Tank Digital Leaders in Health.
    [Show full text]
  • List of Speakers (In Alphabetical Order)
    List of speakers (in alphabetical order) Dr. Laurent Abel Head, Laboratory of Human Genetics of Infectious Diseases INSERM - Paris Descartes University - Imagine Institute for Genetic Diseases, FRANCE Pr. Moulay Hicham Afif Professor of pulmonology at the Faculty of Medicine and Pharmacy of Casablanca - Director of Ibn Rochd University Hospital Center in Casablanca - Head of pulmonology department at Ibn Rochd University Hospital Center - President of Moroccan society of Respiratory Diseases - President of Moroccan univerity college of pulmonology - Member of scientific advisory committee of national program for prevention and control of influenza and acute respiratory infections, Ministry of Health - Faculty of Medicine and Pharmacy, Hassan II University & Ibn Rochd University Hospital Center, Casablanca - Ibn Rochd University Hospital Center, Casablanca, Faculty of Medicine and Pharmacy, Hassan II University & Ibn Rochd University Hospital Center, Casablanca, MOROCCO Dr. Avelin F. Aghokeng Virologist – Joint Research Unit MIVEGEC - Department of Virology - Research Institute for Development and University of Montpellier, France - Director of CDC Virology Laboratory - Centers for Disease Control and Prevention (CDC) - U.S. President's Emergency Plan for AIDS Relief - Global AIDS Program (GAP), Abidjan, Côte d’Ivoire - Institute for research and development (IRD), Montpellier, France - Coordinator of the “HIV DRUG RESISTANCE IN SOUTH” Group at ANRS – France - Expert Member of the WHO HIVResNet Laboratory Working Group for surveillance of HIV Drug Resistance, Member of the ANRS Scientific Expert Panel - Virology Laboratory, Yaoundé, CAMEROUN- International center of medical research of Franceville, GABON Pr Jean François Allilaire Permanent executive officer of French Academy of medicine, FRANCE Pr. Christian Boitard Member of the National Academy of Medicine - Professor of Clinical Immunology - Université de Paris - Director, Institute Physiopathology, Metabolism, Nutrition (AVIESAN), FRANCE Dr.
    [Show full text]
  • UNESCO Paris
    VALUE-BASED HEALTH CARE IN THE DIGITAL ERA December 18, 2018 UNESCO Paris Sous le haut patronage de Madame Agnès Buzyn, ministre des Solidarités et de la Santé 2ND EDITION - INTERNATIONAL CONFERENCE SCIENTIFIC COMMITTEE’S MEMBERS SCIENTIFIC COMMITTEE’S CHAIRMAN We stand at an inflection point. Health systems and stakeholders are increasingly being Ran Balicer (ISR) David Bates (USA) Adam Donglei Feng (CHN) held accountable for the value their actions and products provide to patients and society at Founder and Director Professor of Health General Manager & Co- large. Healthcare ought to be driven by a relentless focus on delivering outcomes that truly Clalit Research Policy & Management, founder Shanghai SimMed Institute Harvard T.H . Chan Technology Co matter to patients. However, the emergence of value-based health care is hindered by a lack School of Public Health of transparent and standardized outcome data. Digital solutions can play an instrumental role in transforming health systems in an unprecedented way. But how do we get there? We invite you to join leaders & pioneers from around the world to share experience on pilots & initiatives around the implementation of value-based health care, the adoption of digital standards, to expectations in payment reforms and access to quality healthcare. Detlev Ganten (GER) Véronique L. Roger (FRA) Lise Rochaix (FRA) Gregory Katz President & Founder Founding Director Center for Chair Hospinomics, Chair of Innovation Management & Value in Health University Paris- World Health Summit the Science of Health Care University Paris-Sorbonne Descartes Medical School, Director of Research, Elsan, Chairman of the Think Delivery Mayo Clinic & Paris School of Economics tank Digital leaders in Health.
    [Show full text]